Stoke Therapeutics, Inc. (STOK) | Investment Case

1. Company Snapshot

1.a. Company Description

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.

It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc.for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system.The company was formerly known as ASOthera Pharmaceuticals, Inc.

and changed its name to Stoke Therapeutics, Inc.in May 2016.Stoke Therapeutics, Inc.

was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Show Full description

1.b. Last Insights on STOK

Stoke Therapeutics' recent performance was driven by a series of positive developments. The company's Q1 earnings and revenue exceeded expectations, with a quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. Additionally, the company's pipeline includes promising programs for SYNGAP-1, Rett syndrome, and ADOA, with industry validation via impressive new partnerships with Biogen and Acadia. Furthermore, the company announced the presentation of data from studies of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress, showcasing improvements in cognition and behavior at Week 68.

1.c. Company Highlights

Last Price	30.87
Change Percentage	-0.58%
Open	31.13
Previous Close	31.05
Market Cap ( Millions)	1763
Volume	582684
Year High	38.69
Year Low	5.35
M A 50	28.74
M A 200	16.26

FCF Yield	2.97%
Dividend Yield	0.00%
ROE	13.28%
Debt / Equity	0.00%
Net Debt / EBIDTA	-291.13%
Price To Book	5.87
Price Earnings Ratio	44.6
Price To FCF	33.67
Price To sales	8.57
EV / EBITDA	58.64

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Analysts

Nov -27

Source: defenseworld.net

Aviva PLC Takes $499,000 Position in Stoke Therapeutics, Inc. $STOK

Nov -14

Source: defenseworld.net

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates

Nov -05

Source: zacks.com

Stoke Therapeutics (STOK) Projected to Post Earnings on Tuesday

Nov -02

Source: defenseworld.net

Stoke Therapeutics, Inc. $STOK Shares Bought by KLP Kapitalforvaltning AS

Oct -22

Source: defenseworld.net

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

Oct -20

Source: businesswire.com

Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?

Oct -09

Source: zacks.com

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Aug -25

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Antisense Oligonucleotide

Expected Growth: 11.3%

Stoke Therapeutics' Antisense Oligonucleotide growth is driven by increasing demand for novel treatments for genetic diseases, advancements in RNA-based therapies, and strategic partnerships. The company's proprietary TANGO platform enables targeted therapies, while its focus on rare diseases and orphan indications fuels growth. Strong clinical trial results and regulatory approvals further support the 11.3% growth.

7. Detailed Products

STK-001

STK-001 is a proprietary antisense oligonucleotide (ASO) designed to treat Dravet syndrome, a rare and severe form of epilepsy.

STK-002

STK-002 is an antisense oligonucleotide (ASO) designed to treat autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disorder.

STK-003

STK-003 is an antisense oligonucleotide (ASO) designed to treat SCN8A-related epilepsy, a rare and severe form of epilepsy.

8. Stoke Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Stoke Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.

Bargaining Power Of Customers

Stoke Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power among individual customers.

Bargaining Power Of Suppliers

Stoke Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market.

Threat Of New Entrants

Stoke Therapeutics, Inc. has a high threat of new entrants due to the attractiveness of the market and the presence of potential entrants.

Intensity Of Rivalry

Stoke Therapeutics, Inc. operates in a highly competitive market with intense rivalry among existing players.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	4.11%
Debt Cost	7.98%
Equity Weight	95.89%
Equity Cost	7.98%
WACC	7.98%
Leverage	4.28%

11. Quality Control: Stoke Therapeutics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stoke Therapeutics

A-Score: 4.4/10

Value: 1.3

Growth: 5.2

Quality: 8.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

IGM Biosciences

A-Score: 3.8/10

Value: 9.4

Growth: 7.1

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

Editas Medicine

A-Score: 3.3/10

Value: 6.2

Growth: 3.9

Quality: 3.6

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

Beam Therapeutics

A-Score: 3.2/10

Value: 6.6

Growth: 3.2

Quality: 3.7

Yield: 0.0

Momentum: 4.0

Volatility: 1.7

1-Year Total Return ->

AIM ImmunoTech

A-Score: 3.1/10

Value: 8.0

Growth: 4.3

Quality: 6.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

Precision BioSciences

A-Score: 3.0/10

Value: 6.6

Growth: 5.0

Quality: 3.5

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

48.91%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

7.98%

Stoke Therapeutics, Inc. - US86150R1077

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on STOK

1.c. Company Highlights

Lower Growth

Medium Volatility

Average Quality

Earnings Beats

Revenues Beats

Strong Momentum

Stable Momentum

Average Growth

Weak Momentum

Better Quality

Fairly Valued

Expensive

Earnings Miss

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Antisense Oligonucleotide

Expected Growth: 11.3%

7. Detailed Products

STK-001

STK-002

STK-003

8. Stoke Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Stoke Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

30.87$

Current Price

30.87$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA